GlassScriptPhysician profile
Samuel Asher Winston
NPI 1346536562
$3,956.75
in general payments reported to CMS, 2019-2025
20 companies · $875 in 2025
The $875 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $894 · 2020: $339 · 2021: $398 · 2022: $499 · 2023: $291 · 2024: $660 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,779 · Consulting Fee: $48.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,778.72 |
| Consulting Fee | $48.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $586.47 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $527.40 | 2019-2025 | Acuvue |
| Allergan, INC. | $383.86 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $365.39 | 2019-2025 | Cequa |
| Alcon Vision LLC | $356.16 | 2019-2025 | Dailies Total1, Tryptyr, Eysuvis |
| Bausch & Lomb Americas INC. | $329.10 | 2022-2025 | Xiidra, Miebo, Infuse |
| Novartis Pharmaceuticals Corporation | $328.66 | 2019-2023 | |
| Abbvie INC. | $232.69 | 2022-2025 | Lumigan, Alphagan P |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $165.28 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $130.88 | 2021-2024 | Acthar |
| Oyster Point Pharma, INC. | $94.06 | 2022-2024 | Tyrvaya |
| Coopervision INC. | $71.86 | 2020 | |
| Integra Lifesciences Corporation | $67.54 | 2019 | |
| Harrow Eye, LLC | $62.46 | 2024 | Vevye |
| Shire North American Group INC | $61.25 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abb Con-Cise Optical Group LLC | $54.65 | 2019 | |
| Optovue, INC. | $45.34 | 2021 | |
| Horizon Therapeutics Plc | $38.32 | 2021-2022 | |
| Dompe US, INC. | $31.40 | 2024-2025 | Oxervate |
| Biotissue Holdings INC. | $23.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Winston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.